Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the ...

A jury awarded $6 million in damages to scientist David Sabatini, whose career imploded after he was accused by a much younger colleague of inappropriate sexual conduct in his lab.

Working conditions are the larger problem. Burnout, chronic understaffing, and high turnover are among the most consistent ...

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

As I prepared for my appointment, the hospital asked me to sign its registration forms and to sign up for MyChart. In the ...

Ahead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most significant news ...

At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared ...

The legal and medical issues in the Christa Pike case are on a collision course,” writes bioethicist M. Sara Rosenthal.

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.